All In Biotech

Drug Trial Radar · NCT05238701

A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 Sustained-release Tablets in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jan 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

104

Actual

Start

Feb 25, 2022

Primary completion

Nov 4, 2023

Study completion Nov 4, 2023

Sponsor

Lead sponsor
Luye Pharma Group Ltd.Industry
Sponsor type
Industry
First posted
Feb 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, randomized, double-blinded, placebo-controlled, dose escalation trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy subjects under fasting state, providing the rationale information for subsequent clinical trials.

Conditions

  • Huntington Disease
  • Tardive Dyskinesia

Interventions

  • LPM3770164 sustained release tabletDrug

    LPM3770164 sustained release tablet will be administrated orally single-dose on day 1

  • LPM3770164 sustained release tablet simulantDrug

    LPM3770164 sustained release tablet simulant will be administrated orally single-dose on day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse effectsTime frame: from baseline to day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Mental Health Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.